Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Oncology Institute (DFPH) Gross Profit (2021 - 2025)

Historic Gross Profit for Oncology Institute (DFPH) over the last 5 years, with Q3 2025 value amounting to $18.9 million.

  • Oncology Institute's Gross Profit rose 3169.98% to $18.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $312.1 million, marking a year-over-year increase of 10942.12%. This contributed to the annual value of $206.5 million for FY2024, which is 4420.41% up from last year.
  • According to the latest figures from Q3 2025, Oncology Institute's Gross Profit is $18.9 million, which was up 3169.98% from $68.7 million recorded in Q2 2025.
  • In the past 5 years, Oncology Institute's Gross Profit ranged from a high of $167.2 million in Q4 2024 and a low of $14.4 million during Q3 2024
  • Its 5-year average for Gross Profit is $41.5 million, with a median of $33.0 million in 2022.
  • Data for Oncology Institute's Gross Profit shows a peak YoY increase of 34669.46% (in 2024) and a maximum YoY decrease of 6125.05% (in 2024) over the last 5 years.
  • Over the past 5 years, Oncology Institute's Gross Profit (Quarter) stood at $25.0 million in 2021, then skyrocketed by 32.41% to $33.0 million in 2022, then increased by 13.26% to $37.4 million in 2023, then surged by 346.69% to $167.2 million in 2024, then plummeted by 88.68% to $18.9 million in 2025.
  • Its Gross Profit stands at $18.9 million for Q3 2025, versus $68.7 million for Q2 2025 and $57.3 million for Q1 2025.